Endo/BioDelivery File Regulatory Application for Pain Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:45PM CST
Endo International along with its partner BioDelivery Sciences International, Inc. announced the submission of a new drug application for buprenorphine HCl buccal film.
BDSI: 12.65 (+0.66), ENDP: 72.10 (+0.34), AUXL: 34.40 (+0.18), AMGN: 160.67 (+3.15)
12.9% Return Seen to Date on SmarTrend BioDelivery Sciences Call (BDSI)
Comtex SmarTrend(R) - Wed Dec 24, 9:31AM CST
SmarTrend identified a Downtrend for BioDelivery Sciences (NASDAQ:BDSI) on November 20th, 2014 at $14.55. In approximately 1 month, BioDelivery Sciences has returned 12.95% as of today's recent price of $12.66.
BDSI: 12.65 (+0.66)
Strong On High Volume: BioDelivery Sciences International (BDSI)
at The Street - Wed Dec 24, 9:01AM CST
Trade-Ideas LLC identified BioDelivery Sciences International (BDSI) as a strong on high relative volume candidate
BDSI: 12.65 (+0.66)
Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain
PR Newswire Europe - Tue Dec 23, 3:15PM CST
Endo Pharmaceuticals Inc., a subsidiary of Endo International plc , and BioDelivery Sciences International, Inc. announced today that they have submitted a New Drug Application (NDA) for Buprenorphine HCl Buccal Film to the U.S. Food and Drug Administration (FDA). Buprenorphine HCl Buccal Film is under development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
BDSI: 12.65 (+0.66), ENDP: 72.10 (+0.34), ENL.TO: 83.00 (+0.91)
BioDelivery Sciences International (BDSI) Marked As A Dead Cat Bounce Stock
at The Street - Fri Dec 19, 8:45AM CST
Trade-Ideas LLC identified BioDelivery Sciences International (BDSI) as a "dead cat bounce" (down big yesterday but up big today) candidate
BDSI: 12.65 (+0.66)
Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 12.65 (+0.66), ACRX: 6.61 (+0.06), EGLT: 5.97 (+0.21), AMGN: 160.67 (+3.15), NKTR: 15.02 (+0.23)
Insider Trading Alert - BDSI, LDRH And LNKD Traded By Insiders
at The Street - Wed Dec 17, 10:42AM CST
Stocks with insider trader activity include BDSI, LDRH and LNKD
BDSI: 12.65 (+0.66), LDRH: 33.82 (-0.26), LNKD: 231.83 (+0.34)
BioDelivery Sciences Down 13.0% Since SmarTrend Downtrend Call (BDSI)
Comtex SmarTrend(R) - Tue Dec 16, 5:25PM CST
SmarTrend identified a Downtrend for BioDelivery Sciences (NASDAQ:BDSI) on November 20th, 2014 at $14.55. In approximately 4 weeks, BioDelivery Sciences has returned 13.03% as of today's recent price of $12.65.
BDSI: 12.65 (+0.66)
BioDelivery Sciences International (BDSI) Strong On High Relative Volume Today
at The Street - Tue Dec 16, 9:02AM CST
Trade-Ideas LLC identified BioDelivery Sciences International (BDSI) as a strong on high relative volume candidate
BDSI: 12.65 (+0.66)
BioDelivery Sciences (BDSI) in Focus: Stock Tanks 11% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 8:02AM CST
BioDelivery Sciences has been witnessing a downward trend in its current year loss estimates and its share price has been falling for past few days
BDSI: 12.65 (+0.66), BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), AFFX: 9.80 (+0.05)
Insider Trading Alert - HPJ, BDSI And MOH Traded By Insiders
at The Street - Mon Dec 15, 1:54PM CST
Stocks with insider trader activity include HPJ, BDSI and MOH
BDSI: 12.65 (+0.66), HPJ: 5.03 (+0.14), MOH: 53.39 (+0.61)
BioDelivery Sciences still rolling over
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:27AM CST
BDSI: 12.65 (+0.66)
BioDelivery Sciences Launches InReach Support Program for Those Affected by Opioid Dependence
PR Newswire - Wed Dec 10, 7:00AM CST
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI), who recently launched BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) for the maintenance treatment of opioid dependence, introduces InReach(TM), a novel support program for those affected by opioid dependence. The program consists of a website (accessible at www.inreachassist.com) and a mobile app (initially available for the iPhone here) that offer a comprehensive array of information and resources to support patients and their families.
BDSI: 12.65 (+0.66)
BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy
PR Newswire - Mon Dec 08, 6:00AM CST
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has completed the randomization of all patients in BDSI's ongoing initial pivotal Phase 3 clinical trial for Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN). BDSI anticipates that topline results of the study will be available by the end of March 2015.
BDSI: 12.65 (+0.66)
What Makes BioDelivery Sciences (BDSI) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 7:38AM CST
BioDelivery Sciences has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past 1 month
BDSI: 12.65 (+0.66), ANIP: 55.24 (+1.79), AMAG: 43.02 (+0.90), AFFX: 9.80 (+0.05)
BioDelivery Sciences to Present at the 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Tue Nov 25, 6:00AM CST
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the 26th Annual Piper Jaffray Healthcare Conference. The presentation is scheduled for Wednesday, December 3, 2014 at 10:30 a.m. Eastern Time at the New York Palace Hotel.
BDSI: 12.65 (+0.66)
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago BioDelivery Sciences Is Down 12.3% (BDSI)
Comtex SmarTrend(R) - Mon Nov 24, 9:00AM CST
When BioDelivery Sciences (NASDAQ:BDSI) reported earnings 19 days ago on November 5th, 2014, analysts, on average, expected the company to report a loss of $0.24 on sales of $5.5 million. The company actually reported a loss of $0.51 per share on sales of $1.8 million, missing EPS estimates by $0.27 and missing revenue estimates by $3.7 million. Since the company's report, shares of BioDelivery Sciences have fallen from $16.30 to $14.29, representing a loss of 12.3% in the past 19 days.
BDSI: 12.65 (+0.66)
Earnings Look Back: BioDelivery Sciences Is Down 11.2% Since Reporting Quarterly Results 1 Week Ago (BDSI)
Comtex SmarTrend(R) - Mon Nov 17, 1:12PM CST
12 days ago, on November 5th, 2014, BioDelivery Sciences (NASDAQ:BDSI) reported its earnings. Analysts, on average, expected a loss of $0.24 per share on sales of $5.5 million. The company actually reported a loss of $0.51 per share on sales of $1.8 million, missing EPS estimates by $0.27 and missing revenue estimates by $3.7 million. Shares of BioDelivery Sciences have slipped from $16.30 to $14.47, representing a loss of 11.2%, since the company reported earnings 12 days ago.
BDSI: 12.65 (+0.66)